Allergan rolls out Viberzi after DEA delay; Sun Pharma unloads Ohio manufacturing unit;

@FiercePharma: Veterinarians debate necessity of dog flu vaccines from Merck and Zoetis. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI Friday: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. Article | Follow @CarlyHFierce

> Allergan ($AGN) launched its irritable bowel syndrome drug Viberzi in the U.S.; the drug won FDA approval earlier this year, but it's been waiting on a scheduling review by the Drug Enforcement Agency. Report

> India-based Sun Pharmaceutical is selling off its manufacturing unit in Bryan, OH, to Nostrum Laboratories. Report

> Alnylam ($ALNY) is planning final trials for ALN-CC5--a paroxysmal nocturnal hemoglobinuria candidate that would compete with Alexion's ($ALXN) pricey Soliris--for 2017. Report

Medical Device News

@FierceMedDev: ICYMI: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. Report | Follow @FierceMedDev

@EmilyWFierce: Lab experts lash out at FDA move to beef up regulation of lab-developed tests. Article | Follow @EmilyWFierce

> St. Jude touts new forms of neurostimulation at Neuromodulation Society meeting. More

> WuXi leads $30M for startup to back Dx for personalized cardio, oncology drug regimens. Article

> App-based glucose monitor implant startup Senseonics reverse-merges to go public in anticipation of CE mark. Story

Biotech News

@FierceBiotech: ICYMI Friday: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report. More | Follow @FierceBiotech

@JohnCFierce: Mitsubishi Tanabe backs Akebia PhIII with a $350M Asian deal for vadadustat. Report | Follow @JohnCFierce

@DamianFierce: The 2015 Biotech IPO Boom, in Requiem. Watch | Follow @DamianFierce

> Roche wins FDA approval for a new lung cancer drug. News

> Another day, another biotech scheme from Martin Shkreli, the master of biopharma disaster. Editor's corner

> $37.5M in hand, Termeer-backed X4 maps a fast pace on cancer immunotherapy R&D. Article

Pharma Marketing News

> Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa. Item

> Shire finally gets Baxalta to the deal-talks table. Article

> Novo Nordisk eyes stepped-up diabetes care in 'beyond the pill' deal with IBM Watson. Story

> Pharma comics partner Medikidz aims to be a child health superhero. Report

> BMS' Opdivo repeats, new flu ads join list of top pharma ad spending for November. More

Animal Health News

> Cornell scientists create first litter of puppies through in vitro fertilization. News

> Report: Antibiotic sales for food animals still on the rise, despite FDA restrictions. Item

> U.K.-based Genus teams with U.S. scientists to create pigs resistant to deadly virus. Story

> Veterinarians debate necessity of dog flu vaccines from Merck and Zoetis. More

> Lilly separates animal health manufacturing but insists it's not prepping a spinoff. Article

Biotech IT News

> GoBalto lands global site activation software deal with Icon. More

> Academics snag EU cash for 3-D genomics project. Report

> SAP makes pitch for precision medicine market with a pair of products. Item

> Analyst: Use of tech to streamline clinical trials 'still early in its adoption cycle.' Story

> Illumina invests in CRISPR gene editing software player. Article

And Finally... Dog owners are wondering whether to vaccinate their dogs against canine influenza virus H3N. More (sub. req.)

Suggested Articles

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.